Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 14(1): 10511, 2024 05 07.
Artigo em Inglês | MEDLINE | ID: mdl-38714773

RESUMO

Cisplatin (CDDP)-induced nephrotoxicity is a common dose-limiting toxicity, and diuretics are often administered to prevent nephrotoxicity. However, the efficacy and optimal administration of diuretics in preventing CDDP-induced nephrotoxicity remain to be established. This study aimed to evaluate the efficacy of combining furosemide and mannitol to prevent CDDP-induced nephrotoxicity. This was a post-hoc analysis of pooled data from a multicenter, retrospective, observational study, including 396 patients who received one or two diuretics for CDDP-based chemotherapy, compared using propensity score matching. Multivariate logistic regression analyses were used to identify risk factors for nephrotoxicity. There was no significant difference in the incidence of nephrotoxicity between the two groups (22.2% vs. 28.3%, P = 0.416). Hypertension, CDDP dose ≥ 75 mg/m2, and no magnesium supplementation were identified as risk factors for nephrotoxicity, whereas the use of diuretics was not found to be a risk factor. The combination of furosemide and mannitol showed no advantage over a single diuretic in preventing CDDP-induced nephrotoxicity. The renal function of patients receiving CDDP-based chemotherapy (≥ 75 mg/m2) and that of those with hypertension should be carefully monitored. Magnesium supplementation is important for these patients.


Assuntos
Cisplatino , Diuréticos , Furosemida , Manitol , Furosemida/efeitos adversos , Furosemida/administração & dosagem , Cisplatino/efeitos adversos , Humanos , Manitol/uso terapêutico , Manitol/administração & dosagem , Masculino , Feminino , Diuréticos/administração & dosagem , Diuréticos/efeitos adversos , Diuréticos/uso terapêutico , Pessoa de Meia-Idade , Estudos Retrospectivos , Idoso , Fatores de Risco , Nefropatias/induzido quimicamente , Nefropatias/prevenção & controle , Quimioterapia Combinada , Antineoplásicos/efeitos adversos , Adulto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA